Isofol Medical AB (ISOFOL)

Market Closed

27 May, 15:25

XSTO

0. 7030

+0.002

+0.29%

118.55M Market Cap

- P/E Ratio

- Div Yield

547,512 Volume

- Eps

kr 0.701

Previous Close

Add Transaction

Day Range

0.701 0.719

Year Range

0.5515 1.738

Want to track ISOFOL and more in your Portfolio? 🎯

Get Started For Free

Summary

ISOFOL closed Wednesday higher at kr0.7, an increase of 0.29% from Tuesday's close, completing a monthly increase of 5.71% or kr0.04. Over the past 12 months, ISOFOL stock lost -2.5%.

ISOFOL is not paying dividends to its shareholders.

The last earnings report, released on May 19, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

ISOFOL Chart

People also search for

AIXIA.B

Aixia Group AB

kr -

ELIC

Elicera Therapeutics AB

kr 2.88

-4.31%

BICO

BICO Group AB

kr 17.5

-4.37%

SANION

Saniona AB (publ)

kr 13.81

-1.64%

INIT

Initiator Pharma A/S

kr 2.94

-1.67%

Isofol Medical AB (ISOFOL) FAQ

What is the stock price today?

The current price is kr0.7030.

On which exchange is it traded?

Isofol Medical AB is listed on XSTO.

What is its stock symbol?

The ticker symbol is ISOFOL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 118.55M.

Has Isofol Medical AB ever had a stock split?

No, there has never been a stock split.

Isofol Medical AB Profile

Biotechnology Industry	Healthcare Sector	Dr. Roger Tell M.D., Ph.D. CEO	XSTO Exchange	SE0009581051 ISIN
Sweden Country	4 Employees	- Last Dividend	- Last Split	- IPO Date

Overview

Isofol Medical AB (publ) is a pivotal player in the biotechnology industry, focusing on the development, commercialization, and international sale of oncology drugs. Established in 2008 and headquartered in Gothenburg, Sweden, Isofol stands at the forefront of clinical stage biotech companies. Through its unwavering commitment to innovation in cancer treatment, the company seeks to offer new hope and enhanced therapeutic options for patients battling cancer, particularly those suffering from advanced colorectal cancer.

Products and Services

Arfolitixorin

At the heart of Isofol Medical AB's product pipeline is arfolitixorin, a novel drug currently in a phase 3 clinical trial. This promising oncology drug is being developed primarily for the treatment of advanced colorectal cancer. Arfolitixorin represents a significant focal point of Isofol's research and development efforts, showcasing the company's commitment to advancing cancer treatment through innovative therapeutic solutions.

Contact Information

Address: Biotech Center

Phone: 46 3 17 97 22 80

Website: https://isofolmedical.com

Blog Affiliate Program About Terms Privacy Help Contact Us